Post Market Surveillance
Highly visible drug recalls, such as Vioxx and Tysabri, have cost the pharmaceutical industry billions of dollars--and lives. Over the last 12 years, the number of adverse events from newly launched drugs has more than doubled.
Consequently, providers and payers are becoming increasingly concerned about the safety, cost and effectiveness of new treatments, and the FDA is seeking more comprehensive “pharmacovigilance” tracking processes and systems. BBN is exploring technologies that track and monitor patient outcomes to provide low-signal pattern detection of adverse events and report this information back to physicians.
